[ad_1]
This press release was originally distributed by SBWire
Albany, NY – (SBWIRE) – 22/02/2019 – Cancers are characterized by the growth and spread of abnormal cells. If the uncontrolled growth of abnormal cells begins in the woman's reproductive organs such as the cervix or the ovaries, then we talk about gynecological cancer. Several factors are responsible for the occurrence of a gynecological cancer. Genes of cancerous origin, also called oncogenes, are mainly responsible for the abnormal growth of cells. Infertility, obesity, mutations, smoking, environmental influences and the early onset of menstruation are among the factors responsible for gynecological cancers.
See the report: https://www.transparencymarketresearch.com/gynecological-cancers-market.html
Gynecological cancers are also caused by viruses such as human papillomavirus, which causes cervical cancer and vulvar cancer. Many women do not have symptoms in the early stages of cancer. However, in the later stages, badl discharge, pain and bleeding occur during intercourse. There are several methods to treat gynecological cancers and the treatment depends on the type of cancer and its extension. Regular screening and self-examination can be helpful for early detection of cancer.
Based on the type of cancer, the global market for gynecological cancers can be segmented into uterine cancer, ovarian cancer, cervical cancer, badl cancer and vulvar cancer. The uterine cancer segment is expected to experience significant growth over the forecast period due to the growing prevalence of obesity. Obese women have high levels of estrogen compared to progesterone, which increases the risk of uterine cancer. In terms of treatment, the market for gynecological cancers can be separated into surgery, chemotherapy, radiotherapy, etc. The segment of surgery is expected to grow at a significant pace from 2017 to 2025 because surgery is the immediate invasive procedure that involves removing damaged cells or tissues from the affected organ. The rising incidence of cancer, particularly cancers of the uterus and ovary, is one of the main drivers of the global market for gynecological cancers. The increasing number of smokers and the increasing prevalence of obesity have resulted in a high incidence of different gynecological cancers. In addition, initiatives by various governments to raise public awareness of cancer are driving the growth of the global market for gynecological cancers. However, the patent expiry of some drugs, the longer recovery process, the low level or the lack of repayment in developing countries are factors that dampen the market in these countries.
Request a report brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37844
In terms of region, the global market for gynecological cancers can be segmented into North America, Europe, Asia-Pacific, Latin America, Middle East and Africa. North America dominates the world market. It is expected to be a significant part of the global market between 2017 and 2025, due to the rising prevalence of gynecological cancers in the region. According to the American Cancer Society, in 2014, a total of 52,630 new cases of uterine cancer were reported and, in 2015, the number of patients increased to 54,870. Lifestyle-related factors, such as obesity, lack of physical activity and hormone replacement therapy, have resulted in an increase in the prevalence of uterine cancer. According to Cancer Research UK, about 37% of uterine cancers are caused by obesity.
This propels the market for gynecological cancers in Europe. Growth in the health care sector, increased public awareness of gynecological cancers and their effects, and an increase in the geriatric population are key factors in stimulating the gynecological cancer market in Asia-Pacific. Advances in diagnostic techniques, increased per capita income, improved quality of life and the growing incidence of cervical cancer in Africa are likely to increase the gynecological cancer market in the Middle East and Africa during the forecast period.
Ask for the table of contents @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=37844
The main players in the global market for gynecological cancers are Becton Dickinson and Co., Bristol Myers Squibb Co., Merck & Co., Pfizer, GlaxoSmithKline plc, Eli Lilly and Co. and F. Hoffmann La Roche Ltd.
About market research for transparency
Transparency Market Research (TMR) is a commercial information company that provides global business information reporting and services. Our exclusive combination of quantitative forecasting and trend badysis provides forward-looking information to thousands of decision makers. TMR's experienced team of badysts, researchers and consultants use proprietary data sources and various tools and techniques to gather and badyze information. Our commercial offers represent the latest and most reliable information that companies need to maintain a competitive advantage.
Each TMR subcontracted research report covers a different sector – such as pharmaceuticals, chemicals, energy, food and beverages, semiconductors, medical devices, consumer goods and technology. These reports provide in-depth badysis and in-depth segmentation at the micro levels possible. With a broader scope and a stratified research methodology, the underwritten TMR reports strive to offer customers the answers to their research needs.
Contact us
Market Research on Transparency
90 State Street, Suite 700
Albany, NY 12207
Tel: + 1-518-618-1030
United States – Canada toll-free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com
For more information on this press release, visit: http://www.sbwire.com/press-releases/gynecological-cancers-market/release-1154479.htm
[ad_2]
Source link
